PriceTargets.com logo

Forty Seven - FTSV Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$95.51 As of 04/7/2020 01:00 AM ET
+0 (0.00%)
Get New Forty Seven Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FTSV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FTSV

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Forty Seven in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $95.51.

This chart shows the closing price for FTSV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Forty Seven. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/4/2020MizuhoDowngradeBuy ➝ Neutral$95.50Low
3/3/2020GuggenheimDowngradeBuy ➝ NeutralLow
3/3/2020SunTrust BanksDowngradeBuy ➝ Hold$55.00 ➝ $95.50Low
3/3/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$45.00 ➝ $95.50Low
3/2/2020Roth CapitalDowngradeBuy ➝ Neutral$95.50Medium
3/2/2020HC WainwrightDowngradeBuy ➝ Neutral$95.50High
2/12/2020MizuhoBoost TargetBuy$37.00 ➝ $53.00Low
2/4/2020GuggenheimReiterated RatingBuy$54.00High
1/26/2020MizuhoReiterated RatingBuy$37.00Low
1/22/2020HC WainwrightReiterated RatingBuy$51.00Medium
1/17/2020OppenheimerBoost TargetOutperform$60.00 ➝ $35.00Low
1/13/2020SunTrust BanksInitiated CoverageBuy$55.00Low
1/10/2020MizuhoReiterated RatingBuy$37.00High
1/7/2020Roth CapitalBoost TargetBuy$35.00 ➝ $55.00High
12/11/2019GuggenheimReiterated RatingBuy$20.00 ➝ $48.00Medium
12/10/2019Roth CapitalBoost TargetBuy$28.00 ➝ $35.00Medium
12/10/2019HC WainwrightReiterated RatingBuy$21.00 ➝ $36.00High
12/10/2019Morgan StanleyBoost TargetOverweight$17.00 ➝ $45.00High
12/10/2019CitigroupBoost TargetOutperform$20.00 ➝ $35.00High
12/10/2019BTIG ResearchReiterated RatingBuy$40.00High
12/10/2019MizuhoReiterated RatingBuy$18.00 ➝ $37.00High
12/5/2019Credit Suisse GroupReiterated RatingOutperform$15.00 ➝ $18.00High
11/20/2019GuggenheimInitiated CoverageBuy$20.00High
11/13/2019HC WainwrightReiterated RatingBuy$21.00High
11/12/2019MizuhoReiterated RatingBuy$18.00High
9/11/2019MizuhoInitiated CoverageBuy$18.00High
8/14/2019OppenheimerLower Target$35.00 ➝ $20.00High
7/12/2019HC WainwrightSet TargetBuy$21.00Medium
5/29/2019Roth CapitalInitiated CoverageBuy ➝ Buy$18.00 ➝ $28.00Low
5/14/2019HC WainwrightSet TargetBuy$21.00Medium
(Data available from 4/26/2019 forward)

News Sentiment Rating

-0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Forty Seven logo
Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $95.51
Low: $95.51
High: $95.51

50 Day Range

MA: $95.51
Low: $95.51
High: $95.51

52 Week Range

Now: $95.51
Low: $5.53
High: $95.51

Volume

N/A

Average Volume

1,606,836 shs

Market Capitalization

$4.60 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4

Frequently Asked Questions

What sell-side analysts currently cover shares of Forty Seven?

The following equities research analysts have issued stock ratings on Forty Seven in the last year:
View the latest analyst ratings for FTSV.

What is the current price target for Forty Seven?

0 Wall Street analysts have set twelve-month price targets for Forty Seven in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Forty Seven in the next year.
View the latest price targets for FTSV.

What is the current consensus analyst rating for Forty Seven?

Forty Seven currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for FTSV.

What other companies compete with Forty Seven?

Other companies that are similar to Forty Seven include BridgeBio Pharma, Organon & Co., Madrigal Pharmaceuticals, Nuvalent and Alpine Immune Sciences. Learn More about companies similar to Forty Seven.

How do I contact Forty Seven's investor relations team?

Forty Seven's physical mailing address is 1490 O`BRIEN DRIVE SUITE A, MENLO PARK CA, 94025. The company's listed phone number is 650-352-4150 and its investor relations email address is [email protected]. The official website for Forty Seven is www.fortyseveninc.com. Learn More about contacing Forty Seven investor relations.